Fabre-Kramer Pharmaceuticals focuses on compounds to license-in, develop for global registration, and license-out to commercial partners. Fabre-Kramer then creates life-cycle management strategies to maximize the commercial potential of those compounds.
In- and Out-Licensing
Fabre-Kramer Pharmaceuticals forms partnerships with individual researchers, research institutions, pharmaceutical as well as biotechnology companies, to license-in molecules for development and further license them out for commercialization.
FKP’s main therapeutic areas of activity are psychiatry and neurology.
Once a candidate is licensed-in, a dedicated, experienced, and multidisciplinary project management team is established to obtain marketing authorizations in major markets, i.e. North America, Europe and Japan.
Shared Objectives with Licensors
As Fabre-Kramer Pharmaceuticals does not conduct sales and marketing, only a rapid and successful registration, along with superior marketing guarantee the Company’s return on investment, sustainability, and viability. Fabre-Kramer grants a significant share of downstream profits to the licensor.